IDH1 and cholangiocarcinoma: In addition, a Phase 3 clinical trial showed improved progression-free survival in patients with advanced, IDH1-mutant cholangiocarcinoma treated with ivosidenib compared with placebo (median 2.7 months [95% CI 1.6–4.2] vs. 1.4 months [1.4–1.6]) (Abou-Alf et al., 2020).